Combining Rosuvastatin With Angiotensin-Receptor Blockers of Different PPARγ-Activating Capacity: Effects on High-Density Lipoprotein Subfractions and Associated Enzymes. (January 2015)

• Record Type: Journal Article
• Authors: Rizos, Christos V.; Liberopoulos, Evangelos N.; Tellis, Kostas; DiNicolantonio, James J.; Tselepis, Alexandros D.; Elisaf, Moses S.
• Is Part Of: Angiology. Volume 66:Number 1(2015)
• Page Start: 36
• Page End: 42
• Publication Date: 2015-01
• Subjects: rosuvastatin -- telmisartan -- olmesartan -- irbesartan -- high-density lipoprotein cholesterol -- lipoprotein-associated phospholipase A2 -- paraoxonase; Blood-vessels -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; 616.13005
• DOI: 10.1177/0003319713512556
• Languages: English
• ISSNs: 0003-3197

Abstract

The effects of combining angiotensin-receptor blockers of different peroxisome proliferator-activated receptor γ-activating capacity with rosuvastatin on high-density lipoprotein (HDL) subfractions and associated enzymes in patients with mixed dyslipidemia, hypertension, and prediabetes were assessed. Patients (n = 151) were randomly allocated to rosuvastatin (10 mg/d) plus telmisartan 80 mg/d (RT group, n = 52) or irbesartan 300 mg/d (RI group, n = 48) or olmesartan 20 mg/d (RO group, n = 51). Total and intermediate HDL cholesterol (HDL-C) levels did not change in any group. Large HDL-C increased, while small HDL-C decreased significantly in all the groups ( P = not significant between the groups). The mass of HDL lipoprotein-associated phospholipase A2 (HDL-Lp-PLA2 ) and the activities of paraoxonase 1 remained unchanged in all the groups. However, HDL-Lp-PLA2 activity increased only in the RT group (+21.4%; P < .01 vs baseline) and did not change in the RI (−4.3%; P = .005 vs RT group) and RO (+3.2%; P = .01 vs RT) groups. In conclusion, only the combination of rosuvastatin with telmisartan increased the possibly antiatherosclerotic HDL-Lp-PLA2 activity.